Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus
For percentage of patients achieving specified reduction in disease activity, iberdomide superior to placebo only at highest dose tested
For percentage of patients achieving specified reduction in disease activity, iberdomide superior to placebo only at highest dose tested
A review of regulatory and drug development status updates.
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Lower serum IgG anti-dsDNA antibody levels seen at 52 weeks with belimumab rather than placebo given after rituximab
Recent approval of new drugs for lupus nephritis and promising therapies on the horizon bode well for the care of patients with the kidney disorder.
This slideshow shows drug information for Saphnelo. Click here for the complete Saphnelo monograph.
The FDA authorizes a postexposure prophylaxis for COVID-19; A new treatment is okay’d for lupus; A higher dose naloxone nasal spray became available; The risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.
The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…
A 28-year-old woman presents with fever and a diffuse rash. One year ago, the woman was at the hospital dermatology department with fever, malar rash, arthralgia, and hematuria. Her medical history documented recurrent painful oral ulcers and photosensitivity. The diagnostic workup at that time revealed systemic lupus erythematosus (SLE) with cutaneous and renal involvement. The…